Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Creative Commons License

Gungor B., Yagci F. C. , GÜRSEL İ., GÜRSEL M.

ONCOIMMUNOLOGY, cilt.3, 2014 (SCI İndekslerine Giren Dergi) identifier


Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.